Drug Profile
Lyme disease therapeutic - LondonPharma
Alternative Names: Artemisinin-based Lyme disease therapeutic - LondonPharma; Lyme disease repurposed therapeutic - LondonPharmaLatest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator LondonPharma
- Class Artemisinins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Lyme disease
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for phase-I development in Lyme-disease in United Kingdom (Sublingual, Spray)
- 26 Nov 2014 Phase-I clinical trials in Lyme disease in United Kingdom (Sublingual) before November 2014
- 13 Jul 2014 Lyme disease therapeutic - LondonPharma is available for licensing as of 17 Dec 2014.